脚手架技术市场份额，规模，趋势，行业分析报告，按类型（水凝胶，聚合物支架，微透明理由表面微孔板，基于纳米纤维的支架）;通过申请;通过疾病类型;通过最终使用;按地区;分部预测，2021 - 2028

报告摘要

The global scaffold technology market was valued at USD 1.11 billion in 2020 and is expected to grow at a CAGR of 9.1% during the forecast period. Prominent factors responsible for the market growth include the high demand for reconstruction surgeries among high net-worth individuals and easier organ transplantation procedures all over the globe. Biomimetic tissue is usually responsible to generate scaffold technology to generate 3D organotypic structures to eases up transplantation processes, thereby boosting the market growth.

了解有关此报告的更多信息：request for sample pages

Industry Dynamics

Growth Drivers
Advancements in 2D to 3D cell culture techniques have provided significant opportunities in tissue engineering and cell therapy. Spheroids enhance the efficacy of the mesenchymal stem cells to improve tissue regenerative, reparative, and anti-inflammatory effects, with better survival rates post-transplantation. This has positively impacted the adoption of 3D scaffold cultures.

引入生物支架具有可区分特征，如惰性，生物降解性，产生荧光的能力，用于推动市场增长。此外，产品推出的主要球员也有利​​于市场。例如，2019年8月，Meril Life Sciences收到了其生物脚手架“Meres100 BRS”的批准，用于用于冠状动脉病变。

脚手架技术市场报告范围

脚手架技术市场主要通过类型，应用，疾病类型，最终用途和地区进行分段。

By Type	通过申请	通过疾病类型	通过最终使用	按地区
Hydrogels 聚合物支架 微图案化表面微孔板 基于纳米纤维的脚手架	Stem Cell Therapy, Regenerative Medicine, & Tissue Engineering Drug Discovery Others	Orthopedics, Musculoskeletal, & Spine 癌症 皮肤和整数 牙科 心脏病学和血管 Neurology 泌尿外科 GI，妇科 Others	生物技术和制药行业必威体育app手机版官网 研究Laboratories and Institutes Hospitals and Diagnostic Centers Others	北美（美国，加拿大） 欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) 拉丁美洲（巴西，墨西哥，阿根廷） 中东和非洲（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

应用洞察力

Based on application, the global scaffold technology market is bifurcated into stem cell therapy,再生医学, & tissue engineering, drug discovery, and others. In 2020, the stem cell therapy segment accounted for the largest revenue share. Such a high share is attributed to the extensive use of scaffolds in aesthetic surgeries, soft tissue repairs, tumor repairs, and wound healing.

预计组织修理中的抗微生物剂在组织修理中的组合被预测以改善重建手术。计算技术和制造技术的进步使得具有受控架构的组织支架的发展。

The drug discovery market segment is expected to witness the highest growth rate over the assessment period. This is due to the strong demand for scaffold technology in drug discovery. The ability of 3D cell models to mimic the micro-environment for cell pathways and etiology studies has contributed largely to the market segment’s growth. Moreover, scaffold reagents are primarily used for drug profiling driving the technology demand.

Insight by Disease Type

In 2020, the musculoskeletal market segment accounted for the largest revenue share, owing to rising cases of orthopedic complications. Each year, in the U.S. alone, more than 15 million fractures occur, this comprises 2 million osteoporosis and 1.6 million traumatic fractures. It is being estimated that over 1.6 million grafts are required each year in the U.S., with a huge economic burden of USD 60 billion.

预计神经病学市场部门将以评估期的最快速度增长。这是由于神经系统疾病的研发服务不断上升。必威开户注册例如，2019年1月，加利福尼亚大学和医学工程研究所的研究人员发达了脊髓，使用3D印刷的脚手架。它装有干细胞，在整个器官中产生自身。因此，技术的进步和适当的资金可能会燃料促进市场部门的增长。

Insight by End-Use

In 2020, the生物技术市场分部占收入份额最大。支架在药物筛查和目标验证研究中的广泛应用主要负责如此巨大的份额。此外，这些公司使用技术来提供药物和其他修改。预计医院分部将在研究期间注册最高的市场增长。

The rising grafting technology procedures such as biological scaffolds in hospital settings and rise in cardiovascular surgeries are primarily responsible for the segment’s growth. For instance, Apollo hospitals introduced bio-resorbable vascular scaffold procedures to treat heart-related ailments. Moreover, bridge enhanced ACL repair by the Boston Children Hospital utilizes scaffolding technology to heal torn ligaments.

地理概述

北美占最大的收入份额。导致增长的区域因素包括最近干细胞研究和再生医学的进步，增加了对脚手架技术的研究和资金的增加，以及该地区的技术创新公司的存在。此外，大量的学术机构参与了技术研究，也有利于该地区的增长。

亚太地区预计将在评估期内目睹利润丰厚的增长率。强大的政府关注干细胞研究是有利于技术市场的增长。例如，印度医学理事会（ICMR）和印度再生医学的国家细胞科学协调中心。两者都是参与干细胞治疗和脚手架技术的研究和开发的政府资助组织。

竞争洞察力

The key players operating in the market for scaffold technology are Merck KGaA, Thermo Fisher Scientific, Inc., Pelobiotech, Corning Incorporated, Avacta Life Sciences Limited, Vericel Corporation, Becton, Dickinson and Company, 3D Biotek LLC, Xanofi, Molecular Matrix Inc., REPROCELL Inc., Matricel GmbH, Akron Biotech, Nanofiber Solutions, 4titude, 3D BioMatrix, NuVasive, Inc., Allergan, and Medtronic.